(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.49%) $78.49
(1.77%) $2.18
(0.05%) $2 309.70
(0.52%) $26.83
(0.10%) $966.30
(-0.36%) $0.929
(-1.35%) $10.84
(-0.13%) $0.797
(0.52%) $91.61
4 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases...
Stats | |
---|---|
今日成交量 | 2.54M |
平均成交量 | 2.47M |
市值 | 4.03B |
EPS | ¥0 ( 2024-02-08 ) |
下一个收益日期 | ( ¥0 ) 2024-05-09 |
Last Dividend | ¥0 ( N/A ) |
Next Dividend | ¥0 ( N/A ) |
P/E | -3.13 |
ATR14 | ¥0.196 (1.15%) |
音量 相关性
OncoTherapy Science, Inc. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
OncoTherapy Science, Inc. 相关性 - 货币/商品
OncoTherapy Science, Inc. 财务报表
Annual | 2022 |
营收: | ¥1.13B |
毛利润: | ¥41.69M (3.67 %) |
EPS: | ¥-5.81 |
FY | 2022 |
营收: | ¥1.13B |
毛利润: | ¥41.69M (3.67 %) |
EPS: | ¥-5.81 |
FY | 2022 |
营收: | ¥1.15B |
毛利润: | ¥113.91M (9.87 %) |
EPS: | ¥-13.72 |
FY | 2021 |
营收: | ¥332.48M |
毛利润: | ¥19.54M (5.88 %) |
EPS: | ¥-8.86 |
Financial Reports:
No articles found.
OncoTherapy Science, Inc.
OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。